Basalin®(insulin glargine injection)

Basalin®(insulin glargine injection)
Product Description

Basalin® is an insulin glargine injection developed and produced independently by Gan & Lee Pharmaceuticals. It was launched in China in 2005 and has been approved in almost 20 countries globally. As a long-acting biosimilar insulin, Basalin® is able to stablely control human blood sugar within 24 hours for the treatment of diabetes.

Read more Show less

Gan & Lee

  • CN
  • 2021
    On CPHI since
View company profile
Categories
more categories Show less
Sales Markets
Show more Show less

Gan & Lee

  • CN
  • 2021
    On CPHI since
View company profile

More Products from Gan & Lee (5)

  • GanleeFine®(pen injeciton needle)

    Product GanleeFine®(pen injeciton needle)

    GanleeFine™ is pen needle for single use, collaborately used with insulin pen or prefilled pen for insulin injection. GanleeFine™ has 5 specifications including 0.30x6mm/30G, 0.30x8mm/30G, 0.25x6mm/31G, 0.25x8mm/31G and 0.23x4mm/32G, which can meet different people's injection needs.
  • GanleePen™(reusable insulin pen)

    Product GanleePen™(reusable insulin pen)

    GanleePen is a reusable insulin pen produced by Gan & Lee's wholly-owned subsidiary, Gangan Medical Technology Co., Ltd. It has user-friendly design, big dose window, precise dose and clear reminder for dose adjustment. In addition, GanleePen is made of high-quality and reusable materials. The color of...
  • Prandilin®

    Product Prandilin®

    Prandilin® is an insulin lispro injection developed and produced independently by Gan & Lee Pharmaceuticals. It was launched in China in 2007. As a fast-acting biosimilar insulin, Prandilin® is able to rapidly control human blood sugar 15-20mins after injection before a meal for the treatment of d...
  • Prandilin®25

    Product Prandilin®25

    Prandilin®25 is a premix insulin lispro suspension developed and produced independently by Gan & Lee Pharmaceuticals. It was launched in China in 2014. As a fast-acting biosimilar insulin, Prandilin®25 is able to rapidly and stablely control human blood sugar 15-20mins after injection before a mea...
  • Rapilin™

    Product Rapilin™

    Rapilin™ is insulin aspart injection developed and produced independently by Gan & Lee Pharmaceuticals. It was approved in China in 2020. As a fast-acting biosimilar insulin, Rapilin™ is able to rapidly control human blood sugar 5-10 mins after injection before or between or after a meal for the t...